VUNO and Lunit, two of Korea’s medical artificial intelligence solution providers, will participate in the European Congress of Radiology (ECR) 2022 in Vienna from July 13-17.
Along with the Radiological Society of North America (RSNA), the ECR is the world’s largest radiology conference attended by global radiologists and medical device manufacturers.
Lunit will present five abstracts featuring its AI solutions for chest and breast radiology. In addition, VUNO will display four VUNO Med solutions in the field of radiology that have obtained the CE certification, introducing product use and clinical research results.
One of Lunit’s presentations will demonstrate its AI-powered Imaging Biomarker in Mammography (IBM) for precisely forecasting breast cancer risk with a C-index of 0.684.
The company will also introduce two joint studies with the University of Cambridge to demonstrate the role Lunit INSIGHT MMG could play in double reading screening settings and increasing the detection of interval cancers.
Furthermore, it will highlight the results of a domestic study, which significantly improved prediction capabilities for Covid-19 patients' prognosis and required medical interventions such as mechanical ventilation and the use of ECMO when integrating the Lunit INSIGHT CXR system.
VUNO, for its part, will introduce VUNO Med-LungCT AI, VUNO Med-BoneAge, VUNO Med-Chest X-ray, and VUNO Med-DeepBrain to convey the advantages of solutions that improve the workflow of medical staff and increase diagnostic accuracy and reading efficiency.
The results of two abstracts will confirm the performance of VUNO’s deep learning algorithms for predicting the progression of dementia based on brain magnetic resonance imaging (MRI) and the risk of the precursor to dementia, contributing to earlier patient diagnosis, the company said.
"We will do our best to accelerate overseas business performance at the ECR 2022 by actively introducing our VUNO-Med solutions, which have obtained overseas licenses such as European CE certification and are active in various medical environments." VUNO CEO Lee Ye-ha said.
Lunit CEO Brandon Suh said, “We plan to expand the partnership with global healthcare companies and medical institutions by demonstrating the credibility of our AI-powered diagnostics solutions.”